Search Results
Your search for all items matches 1773 pages
Showing 101 - 150
Patricia A. Ganz, MD, on Early Breast Cancer, Olaparib, Chemotherapy, and Quality of Life
Patricia A. Ganz, MD, of the University of California, Los Angeles, discusses quality-of-life results from the phase III OlympiA study of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer (Abstract GS4-09).
Komal Jhaveri, MD, on Triple-Negative and Metastatic Breast Cancers: New Data on Neratinib, Fulvestrant, and Trastuzumab
Komal Jhaveri, MD, of Memorial Sloan Kettering Cancer Center, discusses the latest updates from the SUMMIT trial, which explored the combinations of neratinib/fulvestrant/trastuzumab and neratinib plus trastuzumab, as well as fulvestrant alone. The combination regimens appeared to benefit patients...
Michael Gnant, MD, on HR-Positive, HER2-Negative Early Breast Cancer: Trial Results With Palbociclib Treatment
Michael Gnant, MD, of the Medical University of Vienna, discusses phase III findings from the PALLAS study, which showed that adding 2 years of palbociclib to ongoing adjuvant endocrine therapy did not improve survival for patients with stage II to III hormone receptor–positive, HER2-negative early ...
François-Clément Bidard, MD, PhD, on Metastatic Breast Cancer: Endocrine Therapy and Palbociclib
François-Clément Bidard, MD, PhD, of the Institut Curie, discusses phase III findings of the PADA-1 study, which showed that optimizing endocrine therapy after detecting the ESR1 mutation in patients with hormone receptor–positive, HER2-negative metastatic breast cancer may double their median...
Javier Cortés, MD, PhD, on Previously Untreated Triple-Negative Breast Cancer: Pembrolizumab Plus Chemotherapy
Javier Cortés, MD, PhD, of the International Breast Cancer Center, discusses the final phase III results of KEYNOTE-355, which showed that pembrolizumab and chemotherapy improved overall and progression-free survival, compared with placebo and chemotherapy, for patients with previously untreated,...
Kevin Kalinsky, MD, on HR-Positive HER2-Negative Breast Cancer: Endocrine Therapy and Chemotherapy
Kevin Kalinsky, MD, of the Winship Cancer Institute at Emory University, discusses updated phase III results from the SWOG S1007 (RxPONDER) study of women with one to three positive lymph nodes, and hormone receptor–positive, HER2-negative breast cancer. The data showed that postmenopausal women...
Peter Schmid, MD, PhD, on Early-Stage Triple-Negative Breast Cancer: Neoadjuvant Treatment With Pembrolizumab and Chemotherapy
Peter Schmid, MD, PhD, of Barts Cancer Institute, discusses phase III findings from KEYNOTE-522, in which researchers found a generally consistent event-free survival benefit among patients with early-stage high-risk triple-negative breast cancer who were treated with neoadjuvant pembrolizumab plus ...
Hans Wildiers, MD, on Metastatic Breast Cancer: Comparing Addition of Eftilagimod Alpha vs Placebo to Paclitaxel
Hans Wildiers, MD, of University Hospitals Leuven, discusses the final results from the phase IIb AIPAC study, which suggested that eftilagimod added to paclitaxel may be of benefit to patients older than 65 years with hormone receptor–positive, HER2-negative metastatic breast cancer after...
Yongbae Kim, MD, on Elective Internal Mammary Node Irradiation in Women With Node-Positive Breast Cancer: Results of a Randomized Phase III Trial
Yongbae Kim, MD, of the Yonsei Cancer Center and Yonsei University College of Medicine, discusses findings that showed the use of internal mammary area irradiation (IMNI) in regional nodal irradiation did not significantly improve disease-free survival for women with node-positive breast cancer....
Matthew Manning, MD, on Resolving Racial Disparities in the Treatment of Breast and Lung Cancers
Matthew Manning, MD, of Cone Health Cancer Center, discusses findings that showed changes to the way cancer care is delivered may help eliminate racial disparities in survival among patients with early-stage lung and breast cancers. Identifying and addressing obstacles that kept patients from...
C. Jillian Tsai, MD, PhD, on Using Radiotherapy to Thwart Tumor Growth in Advanced Cancers
C. Jillian Tsai, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses results from the first randomized trial of stereotactic body radiation therapy (SBRT) to treat oligoprogressive, metastatic lung and breast cancers. The standard of care for patients with these types of tumors is to...
Youssef Zeidan, MD, PhD, on HER2-Positive Breast Cancer: Treatment-Related Cardiotoxicity
Youssef Zeidan, MD, PhD, of Florida International University and the Lynn Cancer Institute, discusses the advances in radiotherapy planning and delivery that have reduced cardiac radiation exposure in patients with HER2-positive breast cancer who are treated with radiotherapy and trastuzumab...
Katherine E. Reeder-Hayes, MD, MBA, on Geography, Breast Cancer Treatment, and Racial Disparities
Katherine E. Reeder-Hayes, MD, MBA, of the University of North Carolina at Chapel Hill, discusses the timeliness of breast cancer care for Black women compared with non-Black women in North Carolina. Her data showed that greater geographic variation exists in the timeliness of breast cancer care...
Hope S. Rugo, MD, on Triple-Negative Breast Cancer: Treatment Findings From KEYNOTE-355 on Pembrolizumab and Chemotherapy
Hope S. Rugo, MD, of the University of California, San Francisco, discusses phase III results from the KEYNOTE-355 study of pembrolizumab plus chemotherapy, which improved overall survival vs chemotherapy alone in patients with previously untreated locally recurrent, inoperable, or metastatic...
Gabriel N. Hortobagyi, MD, on Advanced Breast Cancer Treated With Endocrine Therapy and Ribociclib
Gabriel N. Hortobagyi, MD, of The University of Texas MD Anderson Cancer Center, discusses results from the MONALEESA-2 trial, which showed that adding the CDK4/6 inhibitor ribociclib to first-line hormonal therapy prolongs survival by 1 year for postmenopausal women with hormone receptor–positive, ...
Javier Cortés, MD, PhD, on HER2-Positive Breast Cancer: Trastuzumab Deruxtecan vs Trastuzumab Emtansine
Javier Cortés, MD, PhD, of Barcelona’s IOB Institute of Oncology, discusses phase III data from the DESTINY-Breast03 study, which support trastuzumab deruxtecan becoming the standard of care for second-line treatment of women with HER2-positive metastatic breast cancer (Abstract LBA1).
Helena M. Earl, MBBS, PhD, on HER2-Positive Early Breast Cancer: A Meta-analysis of Trastuzumab Trials
Helena M. Earl, MBBS, PhD, of the University of Cambridge, discusses an individual patient data meta-analysis of noninferiority randomized clinical trials to determine whether a duration of less than the standard of 12 months of adjuvant trastuzumab is noninferior for treatment outcomes in patients ...
HR-Positive/HER2-Positive Metastatic Breast Cancer
In this video, Drs. Sara A. Hurvitz, William J. Gradishar, and Sara M. Tolaney discuss the current treatment landscape for hormone receptor (HR)-positive, HER-positive metastatic breast cancer. Dr. Hurvitz presents the case of a 34-year-old woman with de novo metastatic estrogen...
ER-Positive/HER2-Positive Breast Cancer and Residual Disease
In this video, Drs. Sara A. Hurvitz, William J. Gradishar, and Sara M. Tolaney turn their discussion to treatment options for HER2-positive breast cancer. Dr. Hurvitz presents a case of a 62-year-old woman diagnosed with high-grade cT1N1 estrogen receptor (ER)-positive/progesterone...
HR-Positive/HER2-Negative Early Breast Cancer
In this video, Drs. Sara A. Hurvitz, William J. Gradishar, and Sara M. Tolaney discuss the management of hormone receptor (HR)-positive, HER2-negative early breast cancer. The faculty present the case of a 54-year-old perimenopausal Black woman who has been diagnosed with high-grade T3N1 left...
Newly Diagnosed HER2-Negative Metastatic Breast Cancer
In this video, Drs. Sara A. Hurvitz, William J. Gradishar, and Sara M. Tolaney discuss current treatment options for newly diagnosed HER2-negative metastatic breast cancer. Dr. Hurvitz presents the case of a 49-year-old perimenopausal Latina woman with intermediate-grade T2N1 left breast cancer...
Terry P. Mamounas, MD, MPH, on Breast Cancer: Extended Aromatase Inhibitor Therapy
Terry P. Mamounas, MD, MPH, of the University of Florida Health Cancer Center, discusses results from the NRG Oncology/NSABP B-42 study, which examined the Breast Cancer Index and its ability to predict whether extended treatment with letrozole benefits patients with hormone receptor–positive...
Melinda L. Telli, MD, on Breast Cancer: Neoadjuvant Talazoparib for Early HER2-Negative Disease
Melinda L. Telli, MD, of Stanford University, discusses results of a phase II study on neoadjuvant talazoparib in germline BRCA1/2 mutation–positive, early HER2-negative breast cancer. In this setting, talazoparib monotherapy was active and yielded pathologic complete response rates comparable to...
Priya Rastogi, MD, on Breast Cancer: Predicting the Benefit of Extended Letrozole Therapy
Priya Rastogi, MD, of the University of Pittsburgh, discusses results from the NRG Oncology/NSABP B-42 trial, which evaluated the utility of the 70-gene MammaPrint assay in predicting the benefit of extended letrozole therapy in patients who had completed 5 years of adjuvant endocrine therapy...
Sibylle Loibl, MD, PhD, on Triple-Negative Breast Cancer: Improving Long-Term Outcomes With Durvalumab
Sibylle Loibl, MD, PhD, of the German Breast Group, discusses results from the phase III GeparNUEVO study, which investigated neoadjuvant durvalumab in addition to anthracycline/taxane-based neoadjuvant chemotherapy in patients with early triple-negative breast cancer (Abstract 506).
Geoffrey J. Lindeman, MBBS, PhD, on Breast Cancer: Venetoclax and Fulvestrant in ER-Positive, HER2-Negative Disease
Geoffrey J. Lindeman, MBBS, PhD, of Peter MacCallum Cancer Centre, discusses results from the phase II VERONICA study, which compared venetoclax plus fulvestrant with fulvestrant alone in women with estrogen receptor–positive, HER2-negative, locally advanced or metastatic breast cancer who...
Nadia Harbeck, MD, PhD, on Luminal Breast Cancer: Prognostic Impact of Recurrence Score, Endocrine Response, and Other Factors
Nadia Harbeck, MD, PhD, of Ludwig Maximilian University of Munich, discusses first phase III results from a prospective high-risk cohort of patients with luminal breast cancer, which showed a good prognosis in some women with more than four positive lymph nodes and low recurrence scores. The study...
Nadia Harbeck, MD, PhD, on Early Breast Cancer: Benefit of a De-escalated Regimen
Nadia Harbeck, MD, PhD, of Ludwig Maximilian University of Munich, discusses results from the ADAPT HR–/HER2+ trial, which showed, for the first time, improved pathologic complete response and survival in patients with early breast cancer who were treated weekly with a de-escalated 12-week regimen...
Ingrid A. Mayer, MD, on Triple-Negative Breast Cancer: Platinum-Based Chemotherapy vs Capecitabine
Ingrid A. Mayer, MD, of Vanderbilt University Medical Center, discusses phase III results from a trial that showed patients with triple-negative breast cancer who had residual invasive disease after neoadjuvant chemotherapy had lower-than-expected invasive disease–free survival, regardless of study ...
Massimo Cristofanilli, MD, on Breast Cancer: Updated Analysis on Palbociclib Plus Fulvestrant
Massimo Cristofanilli, MD, of the Feinberg School of Medicine at Northwestern University, discusses updated overall survival data from the phase III PALOMA-3 trial of palbociclib plus fulvestrant in women with hormone receptor–positive, HER2-negative advanced breast cancer (Abstract 1000).
Andrew Tutt, PhD, MBChB, on Breast Cancer: Olaparib After Chemotherapy in Germline BRCA1/2–Mutated Tumors
Andrew Tutt, PhD, MBChB, of the Institute of Cancer Research, London, discusses findings from the phase III OlympiA trial, which showed that adjuvant olaparib, a PARP inhibitor, following adjuvant or neoadjuvant chemotherapy, may improve invasive disease–free survival in patients with germline...
John Marshall, MD, and Liza Marshall: When Cancer Strikes an Oncologist’s Family
John Marshall, MD, of the Lombardi Cancer Center at Georgetown University, and his wife, Liza Marshall, a breast cancer survivor, talk about the impact of her diagnosis, how it changed their view of cancer care and the way clinicians communicate, and why their memoir has an important message.
Melinda L. Telli, MD, on HER2-Positive Breast Cancer: NCCN Guidelines Update
Melinda L. Telli, MD, of Stanford Cancer Institute, discusses highlights of the new NCCN Clinical Practice Guidelines in Oncology®, including nonanthracycline, taxane-based regimens as preferred treatments for patients with HER2-positive breast cancer; newly approved combination therapies such as...
Linda T. Vahdat, MD, MBA, on Triple-Negative Breast Cancer: Targeting the Tumor Microenvironment
Linda T. Vahdat, MD, MBA, of Memorial Sloan Kettering Cancer Center, discusses results of a phase II trial designed to test the concept that targeting the tumor microenvironment by depleting copper may prevent metastases, essentially disrupting the infrastructure that contributes to tumor spread.
Dennis J. Slamon, MD, PhD, on Exploiting Cancer Biology in Developing New Treatment Paradigms
Dennis J. Slamon, MD, PhD, of the UCLA David Geffen School of Medicine, reflects on the ways in which breast cancer research pioneered the targeted treatment approach, as understanding of the basic biology of tumors deepened and new pathways were uncovered. He sees a future ripe with possibilities...
Rita Nanda, MD, on Triple-Negative Breast Cancer: Emerging Therapeutic Strategies
Rita Nanda, MD, of the University of Chicago, discusses the latest data on novel treatment strategies for triple-negative breast cancer, including immune checkpoint, PARP, and ATK inhibitors; antibody-drug conjugates; and targeting the androgen receptor.
William J. Gradishar, MD, on Triple-Negative Breast Cancer: NCCN Guidelines Update
William J. Gradishar, MD, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the latest recommendations from the National Comprehensive Cancer Network for treating patients with triple-negative breast cancer; data on early-stage and advanced disease; and the role...
Ann H. Partridge, MD, MPH, on ER+, HER2– Breast Cancer: More Effective Treatments Needed
Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, discusses results from the ALTERNATE trial on response to neoadjuvant chemotherapy in postmenopausal women with clinical stage II or III estrogen receptor–positive and HER2-negative breast cancer that is resistant to endocrine therapy. The ...
Elizabeth A. Mittendorf, MD, PhD, on Her Plenary Lecture: Local Regional Management Following Neoadjuvant Therapy
Elizabeth A. Mittendorf, MD, PhD, of Brigham and Women’s Hospital, summarizes her plenary talk, which featured the uncertainties in treatment knowledge: excision of postchemotherapy calcifications; the best sentinel lymph node biopsy technique for patients with node-positive disease who convert to...
Sibylle Loibl, MD, on HR+ HER2– Primary Breast Cancer: Palbociclib and Endocrine Therapy
Sibylle Loibl, MD, of the German Breast Group, discusses the first phase III results from the PENELOPE-B study of palbociclib combined with endocrine therapy in patients with hormone receptor–positive, HER2-negative primary breast cancer who are at high risk for relapse after neoadjuvant...
Joyce V. Lee, PhD, on Triple-Negative Breast Cancer: MYC as a Predictor of Treatment Response
Joyce V. Lee, PhD, of the University of California, San Francisco, discusses data that suggest the MYC oncogene may indicate whether a patient with triple-negative breast cancer will respond to immunotherapy. Dr. Lee’s study is the first to describe MYC downregulation of MHC-I and to demonstrate...
Roisin M. Connolly, MD, on HR+ Advanced Breast Cancer: Endocrine Therapy and Entinostat
Roisin M. Connolly, MD, of University College Cork, discusses phase III results from the E2112 trial, which showed exemestane plus entinostat did not improve survival in aromatase inhibitor–resistant advanced HR-positive, HER2-negative breast cancer (Abstract GS4-02).
Lee S. Schwartzberg, MD, on HER2– HR+ Breast Cancer: Tesetaxel and Capecitabine
Lee S. Schwartzberg, MD, of the West Cancer Center, discusses phase III results from the CONTESSA study, which showed that an all-oral regimen of tesetaxel plus a reduced dose of capecitabine significantly improved progression-free survival compared with capecitabine alone in patients with...
Sara A. Hurvitz, MD, on Triple-Negative Breast Cancer: Sacituzumab Govitecan and Chemotherapy
Sara A. Hurvitz, MD, of the David Geffen School of Medicine at UCLA, discusses phase III data from the ASCENT study of the antibody-drug conjugate sacituzumab govitecan vs chemotherapy in patients with previously treated metastatic triple-negative breast cancer (Abstract GS3-06).
Patricia A. Ganz, MD, on Younger Breast Cancer Survivors: Managing Depression
Patricia A. Ganz, MD, of the University of California, Los Angeles, discusses study findings that showed mindfulness meditation and survivorship education may effectively reduce depression and related symptoms such as fatigue and sleep disturbance, which pose serious threats to younger women’s...
Joseph A. Sparano, MD, on HR+, HER2– Breast Cancer: Individualizing Prognosis and Predicting Treatment Success
Joseph A. Sparano, MD, of the Montefiore Medical Center and Albert Einstein College of Medicine, discusses the development and validation of a tool that integrates the 21-gene recurrence score and clinicopathologic features to individualize prognosis for distant recurrence and predict chemotherapy...
Nadia Harbeck, MD, on Early Breast Cancer: Endocrine Therapy After Preoperative Treatment
Nadia Harbeck, MD, of the University of Munich, discusses the first outcome data from the phase III ADAPT HR+/HER– trial, which combined both static and dynamic biomarkers to optimize the adjuvant therapy approach in patients with intermediate- or high-risk luminal early breast cancer (Abstract...
Debra A. Pratt, MD, on Time to Completion of Breast Cancer Treatment and Survival
In her recent study, Debra A. Pratt, MD, of the Cleveland Clinic, showed that when breast cancer treatment using any of three modalities takes longer than 38 weeks, it is associated with a decrease in survival, regardless of the receptor status. Patients with breast cancer who received neoadjuvant...
Chirag Shah, MD, on Assessing DCIS Recurrence Risk
Chirag Shah, MD, of the Cleveland Clinic, discusses the impact of DCISionRT testing on radiation therapy recommendations for patients with ductal carcinoma in situ following lumpectomy. His study found that despite using traditional favorable-risk criteria, radiation recommendations were changed in ...
Alphonse G. Taghian, MD, PhD, on Irradiation for Breast Cancer: Defining the Optimal Dose
Alphonse G. Taghian, MD, PhD, of Massachusetts General Hospital, reviews the 10-year follow-up of a dose-escalation trial studying accelerated partial-breast irradiation and discusses the optimal dose, adverse effects, and cosmetic outcomes (Abstract 25).
